Jin Y, Fang Y, Yao Y. Separating dose schedule from disease biology in CD19 CAR T-cell therapy. Comment on: "A novel dose-dense strategy for CD19-directed CAR T-cell therapy is associated with durable responses without increased toxicity in patients with B-cell non-Hodgkin lymphoma". haematol [Internet]. 2020Sep.10 [cited 2026Jul.29];. Available from: https://haematologica.org/article/view/14320